|
Board of Directors (Current List) Contact Us (Members of NMCCA Staff)
2009 New Mexico Cancer Care Alliance Annual Report
New Mexico Cancer Care Alliance held its seventh annual meeting on October 8, 2009 that brought together many of the participants and affiliates. NMCCA has had an exciting year. The NMCCA sites accrued 518 patients onto our trials, which exceed our goal by 278 patients. This brings the total of patients we have helped since we became operational in the fall of 2003 to over 1167.
NMCCA worked to amend the current cancer clinical trial law regarding insurance coverage for routine care associated with treatment for cancer patients on a clinical trial. Senate Bill 42 (SB42), sponsored by Senator Dede Feldman, passed during the 2009 session and Cancer Clinical Trial Insurance Coverage went into law on Tuesday, April 7, 2009. This law is great news for cancer patients in New Mexico. It requires insurance companies to cover the cost of routine care of cancer patients while on a clinical trial; the law was amended to no longer sunset, include all phases of cancer clinical trials and to include primary prevention trials.
Hematology Oncology Associates and New Mexico Cancer Care Associates were presented with Special Awards for the community sites with the most MBCCOP accruals. UNM Cancer Center was recognized as the NMCCA site with the most accruals.
Number of Patients Accrued to Trials
NMCCA Site |
Number of Accruals |
UNM Cancer Center and UNM @ Lovelace |
369 |
Hematology-Oncology Associates |
56 |
New Mexico Cancer Care Associates |
35 |
Presbyterian Healthcare Services |
22 |
Radiation Oncology Associates |
6 |
Southwest Gynecological Oncology Associates |
2 |
UNM Las Cruces |
22 |
NM VA Medical Center |
1 |
CA site for Dr. Pratt's study |
5 |
Total Patients Accrued to Clinical Trials |
518 |
Time to Open Trials
Measured by NMCCA receipt of protocol to IRB approval for initial site
Goal - 11 Weeks
Range – 10.1 Weeks to 27.3 Weeks
Average – 17.0 Weeks |
Moving Forward
2009-2010 Goals
1. Clinical Trial Program:
a. The average time to open non Investigator Initiated Trials (IIT) clinical trials will be < 13 weeks. As measured by the time for initial IRB approval from the date NMCCA receipts the protocol from the trial sponsor. For Investigator Initiated trials the time to open will be < 17 weeks. Additionally, measure the time from MSRC Approval to IRB submission for non IIT trials to < 4 weeks and for IIT trials < 8 weeks.
b. NMCCA will accrue a minimum of 408 subjects, with 23% on pharmaceutical sponsored trials, 18% on NCI trials, 29% on funded investigator initiated trials and 30% unfunded investigator initiated.
c. Meet the financial performance as approved by the Board on May 14, 2009.
2. Advocate for a bill through the 2010 legislative session aimed at funding Clinical trials expansion and the development of a prevention network.
3. Develop outreach and awareness program to engage referring physicians and primary care physicians to cancer clinical trials.
4. Expand participation outside of the Rio Grande Corridor. Seek additional hospital to our network.
For financial information, please see our IRS Form 990 on the GuideStar database- www.guidestar.org
back to top
updated 11-4-09
|
